Abstract In December 2021, the US Food and Drug Administration (FDA) granted
emergency authorization for Paxlovid® as an antiviral treatment for COVID-19. Paxlovid® is …

A systematic approach is required for the development of an evidence-based risk
assessment tool to robustly estimate the risks and implications of SARS-CoV-2 variants. We …

Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …

We read with great interest the recent article published in the Journal of Infection
investigating the effectiveness of molnupiravir, nirmatrelvir–ritonavir, and sotrovimab in …

Introduction Migraine pharmacological therapies targeting calcitonin gene-related peptide
(CGRP), including monoclonal antibodies and gepants, have shown clinical effect and …

This study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-
Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk …

Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …

Background The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality in high-risk populations. Several therapeutics have been developed …

Currently there is a lack of randomized trial data examining the use of the antiviral
nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection. This target trial …

Background and purpose An enhanced severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) vaccine regimen could improve humoral vaccine response in patients with …